<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163827">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00965419</url>
  </required_header>
  <id_info>
    <org_study_id>11332</org_study_id>
    <secondary_id>H9P-MC-LNDH</secondary_id>
    <nct_id>NCT00965419</nct_id>
  </id_info>
  <brief_title>A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder</brief_title>
  <official_title>Long-Term, Open-Label, Safety Study of LY2216684 in Pediatric Patients With Attention Deficit/Hyperactivity Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of your child's participation in the study is to determine whether
      LY2216684 can help pediatric patients with ADHD, and assess the safety of LY2216684 and any
      side effects that might be associated with it.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      12 week dose titration and response assessment period. One (1) year open label treatment for
      responders. Long-term extension of up to 4 additional years for responders.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to low 5 year completer number and not meeting primary objective.
  </why_stopped>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Events (SAE) of LY2216684; percentage</measure>
    <time_frame>week 0 thru 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Events (SAE) of LY2216684; number</measure>
    <time_frame>week 0 thru 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events (TEAEs); percentage</measure>
    <time_frame>week 0 thru 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation due to adverse events (DCAEs); percentage</measure>
    <time_frame>week 0 thru 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation rates; percentage</measure>
    <time_frame>week 0 thru 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Columbia-Suicide Severity Rating Scale (CSSRS); incident rate for each category</measure>
    <time_frame>week 0, week 12, year 1, year 5, 1-month follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conners Comprehensive Behavior Rating Scales (CP-CBRS) DSM-IV-TR symptom subscale for manic episode and mixed episode; mean change of total score</measure>
    <time_frame>week 0, week 12, year 1, year 5, 1-month follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tanners scale - height, weight, BMI; Z-score change</measure>
    <time_frame>week 0, year 1, year 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tanners scale - sexual maturation; percentage</measure>
    <time_frame>week 0, year 1, year 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tobacco, alcohol and marijuana use; percentage</measure>
    <time_frame>week 0 thru 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) (hyperactive/impulsive, inattentive and total score); mean change of each score</measure>
    <time_frame>week 0, week 12, year 1, year 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions-Attention-Deficit/Hyperactivity Disorder-Severity (CGI-ADHD-S); mean change of total score</measure>
    <time_frame>week 0, week 12, year 1, year 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conners Comprehensive Behavior Rating Scales (CP-CBRS DSM-IV-TR) ADHD symptom subscales (hyperactive/impulsive, inattentive and total score); mean change of each score</measure>
    <time_frame>week 0, week 12, year 1, year 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Teacher-rated Swanson Nolan, and Pelham Rating Scale-Revised (SNAP-IV) ADHD subscales (hyperactive/impulsive, inattentive and total score); mean change of total score</measure>
    <time_frame>week 0, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate; percentage</measure>
    <time_frame>week 0, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response; survival curve</measure>
    <time_frame>week 0, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swanson Nolan, and Pelham Rating Scale-Revised (SNAP-IV) oppositional defiant disorder (ODD) subscale; mean change of total score</measure>
    <time_frame>week 0, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conners Comprehensive Behavior Rating Scales (CP-CBRS) DSM-IV-TR for oppositional defiant disorder (ODD), anxiety, conduct disorder and major depressive episode; mean change of each score</measure>
    <time_frame>week 0, week 12, year 1, year 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child Health and Illness Profile-Adolescent edition (CHIP-AE) in 5 health outcome domains (satisfaction, comfort, resilience, risk avoidance and achievement); mean change of the 5 domain scores</measure>
    <time_frame>week 0, week 12, year 1, year 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child Health and Illness Profile-Child edition (CHIP-CE) in 5 health outcome domains (satisfaction, comfort, resilience, risk avoidance and achievement); mean change of the 5 domain scores</measure>
    <time_frame>week 0, week 12, year 1, year 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conners Comprehensive Behavior Rating Scales (CP-CBRS) impairment items subscales for schoolwork/grades, friendship/relationships, and home life; mean change of total score</measure>
    <time_frame>week 0, week 12, year 1, year 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conners Comprehensive Behavior Rating Scales (CP-CBRS) content subscale for aggressive behaviors, academic difficulties (total/language/,math), social problems, and violence potential), mean change of each total score</measure>
    <time_frame>week 0, week 12, year 1, year 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro-Qol Questionnaire - 5 Dimensions (EQ-5D) for parent, mean change of total score</measure>
    <time_frame>week 0, week 12, year 1, year 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro-Qol Questionnaire - 5 Dimensions (EQ-5D) for child, mean change of total score</measure>
    <time_frame>week 0, week 12, year 1, year 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro-Qol Questionnaire - 5 Dimensions (EQ-5D) for adolescent, mean change of total score</measure>
    <time_frame>week 0, week 12, year 1, year 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Woodcock Johnson III Test of Achievement (WCJ III ACH), mean change of total score</measure>
    <time_frame>week 0, year 1 year 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wide Range Achievement Test (WRAT-IV or WRAT4); mean change of total score</measure>
    <time_frame>week 0, year 1, year 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wechsler Intelligence Scale for Children Fourth Edition (WISC-IV); mean change of total score</measure>
    <time_frame>week 0, year 1, year 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wechsler Adult Intelligence Scale - third Edition (WAIS-III); mean change of total score</measure>
    <time_frame>week 0, year 1, year 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events (TEAEs); number</measure>
    <time_frame>week 0 thru 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation due to adverse events (DCAEs); number</measure>
    <time_frame>week 0 thru 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation rates; number</measure>
    <time_frame>week 0 thru 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tanners scale - sexual maturation; number</measure>
    <time_frame>week 0, year 1, year 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tobacco, alcohol and marijuana use; number</measure>
    <time_frame>week 0 thru 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate; number</measure>
    <time_frame>week 0, week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">266</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>LY2216684</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2216684</intervention_name>
    <description>0.1 mg/kg/day or patient specific known stable dose (rollover patients) up to 0.3 mg/kg/day, oral, daily for up to 5 years.</description>
    <arm_group_label>LY2216684</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Patients must meet Diagnostic &amp; Statistical Manual of Mental Disorders 4th Ed
             diagnostic criteria for ADHD based Kiddie Schedule for Affective Disorders &amp;
             Schizophrenia for School Aged Children - Present and Lifetime Version at screening
             for new patients/rollover patients.

          -  Patients must have an ADHDRS-IV-Parent: Inv total score of at least 1.5 standard
             deviations above the age/gender norm at both screening/randomization. New patients
             must have a CGI-ADHD-S score greater than or equal to 4 at both
             screening/randomization.

          -  Patients of child-bearing potential agree to use a reliable method of birth control
             during the study and for 1 month following the last dose of study drug. Female
             patients of child-bearing potential must test negative for pregnancy at the time of
             enrollment based on a urine pregnancy test.

          -  Patients must have laboratory results, showing no clinically significant
             abnormalities.

          -  Parents/patients must have a degree of understanding sufficient to communicate
             suitably with the investigator/ study coordinator.

          -  Patients must be of normal intelligence.

          -  Patients/parents must have been judged by the investigator to be reliable to keep
             appointments for clinic visits/all tests, including venipunctures and examinations
             required by the protocol.

          -  Patients must be able to swallow tablets.

        EXCLUSION CRITERIA:

          -  Patients who weigh less than 16 kg at screening/randomization.

          -  Female patients who are pregnant/breastfeeding.

          -  Patients who have previously withdrawn/discontinued early from this study or any
             other study investigating LY2216684.

          -  Patients who have a history of Bipolar I/II disorder, psychosis, or pervasive
             developmental disorder.

          -  Patients with a history of any seizure disorder or known electroencephalographic
             (EEG) abnormalities in the absence of seizures.

          -  Patients who are at serious suicidal risk.

          -  Patients with a history of severe allergies to more than 1 class of medications, or
             multiple adverse drug reactions, or known hypersensitivity to LY2216684.

          -  Patients with a history of alcohol or drug abuse/dependence within the past 3 months
             of screening, or who are currently using alcohol, drugs of abuse, or any prescribed
             or over-the-counter medication in a manner that the investigator considers indicative
             of abuse/dependence.

          -  Patients who screen positive for drugs of abuse cannot participate.

          -  Patients who have a medical condition that would increase sympathetic nervous system
             activity markedly, or who are taking a medication on a daily basis that has
             sympathomimetic activity are excluded.

          -  Patients with problems that would be exacerbated by increased norepinephrine tone
             including a history of cardiovascular disease, thyroid dysfunction, glaucoma, or
             urinary retention.

          -  Patients who at any time during the study are likely to need psychotropic medications
             apart from the drugs under study.

          -  Patients who have used a monoamine oxidase inhibitor (MAOI) during the 2 weeks prior
             to randomization.

          -  Patients with current or past history of clinically significant hypertension.

          -  Patients who are currently enrolled in, or discontinued within the last 30 days from
             a clinical trial involving an off-label use of an investigational drug, or
             concurrently enrolled in any other type of medical research judged not to be
             scientifically or medically compatible with this study.

          -  Patients whose family anticipates a move outside the geographic range of the
             investigative site during participation in the study or who plan extended travel
             inconsistent with the recommended visit intervals.

          -  Patients who, in the opinion of the investigator, are unsuitable in any other way to
             participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>University Park</city>
        <state>Florida</state>
        <zip>34201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Smyrna</city>
        <state>Georgia</state>
        <zip>30080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <zip>60048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rochester Hills</city>
        <state>Michigan</state>
        <zip>48307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lake Jackson</city>
        <state>Texas</state>
        <zip>77566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79423</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Herndon</city>
        <state>Virginia</state>
        <zip>20170</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 1Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santurce</city>
        <zip>00912</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kuei Shan Hsiang</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Mexico</country>
  </removed_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 3, 2015</lastchanged_date>
  <firstreceived_date>August 24, 2009</firstreceived_date>
  <firstreceived_results_disposition_date>September 3, 2015</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Phenylethyl Alcohol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
